Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Other Non-Current Assets: 2016-2024

Historic Other Non-Current Assets for Rocket Pharmaceuticals (RCKT) over the last 8 years, with Dec 2024 value amounting to $529,000.

  • Rocket Pharmaceuticals' Other Non-Current Assets rose 2.39% to $515,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $515,000, marking a year-over-year increase of 2.39%. This contributed to the annual value of $529,000 for FY2024, which is 0.75% down from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported Other Non-Current Assets of $529,000 as of FY2024, which was down 0.75% from $533,000 recorded in FY2023.
  • In the past 5 years, Rocket Pharmaceuticals' Other Non-Current Assets ranged from a high of $608,000 in FY2022 and a low of $455,000 during FY2020.
  • Over the past 3 years, Rocket Pharmaceuticals' median Other Non-Current Assets value was $533,000 (recorded in 2023), while the average stood at $556,667.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 33.63% in 2022, then declined by 12.34% in 2023.
  • Yearly analysis of 5 years shows Rocket Pharmaceuticals' Other Non-Current Assets stood at $455,000 in 2020, then remained steady at $455,000 in 2021, then skyrocketed by 33.63% to $608,000 in 2022, then declined by 12.34% to $533,000 in 2023, then fell by 0.75% to $529,000 in 2024.